Sponsor

Formycon AG

Germany Fraunhoferstrasse 15, Martinsried, 82152 Planegg, Germany

About the sponsor

Formycon AG’s clinical research includes cancer treatment in metastatic non-squamous non-small cell lung cancer (NSCLC), with interest in immuno-oncology approaches and checkpoint inhibitor therapy.

Metastatic NSCLC
Non-squamous lung cancer
Immune response

The sponsor’s activity in this area reflects a focus on therapies used alongside chemotherapy for advanced lung malignancies.

About Specializations

Formycon AG runs clinical trials in conditions such as Non-small cell lung cancer metastatic, among others.

Non-small cell lung cancer metastatic

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Non-small cell lung cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing the Effects and Safety of FYB206 and Pembrolizumab with Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Bulgaria

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Formycon AG

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →